- Pliant Therapeutics Inc INTEGRIS-PSC Phase 2a Trial Results Call TranscriptFeb 05, 2024
- Pliant Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Pliant Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Pliant Therapeutics Inc INTEGRIS-PSC Interim Phase 2a Data Presentation TranscriptSep 26, 2023
- Pliant Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 10, 2023
- Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Pliant Therapeutics Inc INTEGRIS-IPF Call TranscriptMay 01, 2023
- Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 19, 2023
- Pliant Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Pliant Therapeutics Inc at Cowen Health Care Conference TranscriptMar 08, 2023
- Pliant Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 15, 2023
- Pliant Therapeutics Inc Review Data from the 320 mg Group of the INTEGRIS-IPF Phase 2a Trial of Bexotegrast (PLN-74809) in Patients with IPF Call TranscriptJan 23, 2023
- Pliant Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- Pliant Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Pliant Therapeutics Inc at RBC Capital Markets Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (Virtual) TranscriptOct 07, 2022
- Pliant Therapeutics Inc to Discuss Results from INTEGRIS-IPF Call TranscriptJul 11, 2022
- Pliant Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2022
- Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 18, 2022
- Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
Pliant Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
The Cantor Global Healthcare Conference. I'm Pete Stavropoulos, biotech analyst at Cantor. With us, we have Pliant Therapeutics, a company I cover. And I'm pleased to introduce Bernard Coulie, President and CEO; and Ãric Lefebvre, CMO.
Welcome to the conference. Let's start off with a bit of an overview of Pliant, the company -- for those who are not familiar with the company.
Absolutely. And thanks, Pete, for having us here at the Cantor conference. Pliant Therapeutics started about seven years ago with a mission and a focus on developing novel therapeutics for fibrotic diseases. To that end, we have built a platform that is addressing integrins, which are known to activate TGF-β, which is the main driver of fibrosis. And by blocking those integrins, we basically block the TGF-β pathway, thereby blocking propagation -- initiation and propagation of fibrosis. So out of that platform, it's a small molecule library, basically unmatched in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)